ID: h-fe39641b
Hypothesis
CHIP E3 Ligase Enhancement to Target Synaptic Proteins for Degradation
CHIP E3 Ligase Enhancement to Target Synaptic Proteins for Degradation.
🧬 CHIP/STUB1 (STIP1 homology and U-box containing protein 1)🩺 proteomics🎯 Composite 47%💱 $0.50▲7.0%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 6 oppose
🧪 Overview
CHIP E3 Ligase Enhancement to Target Synaptic Proteins for Degradation
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Misfolded Tau and APP<br/>Accumulation in Neurons"]
B["Hsp70 Chaperone<br/>Client Recognition"]
C["CHIP/STUB1 E3 Ligase<br/>Cochaperone Binding"]
D["Polyubiquitin Chain<br/>K48-linkage tagging"]
E["26S Proteasome<br/>Substrate Delivery"]
F["Protein Aggregate<br/>Clearance"]
G["Synaptic Protein<br/>Quality Control"]
H["Neuroprotection<br/>Reduced AD pathology"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style C fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports6 contradicts
Supports
CHIP ubiquitinates phosphorylated tau and mutant APP, promoting their degradation
Supports
CHIP protein levels are reduced in AD temporal cortex compared to age-matched controls
Supports
Hsp70 ATPase modulators (KGPP) allosterically enhance CHIP ligase activity toward substrates
Contradicts
CHIP-mediated ubiquitination of tau generates Lys63-linked chains that are NOT degraded but propagate aggregation
Contradicts
CHIP ubiquitinates Akt - impaired insulin signaling and metabolic dysfunction
Contradicts
CHIP's protective effects may derive from cochaperone activity, not ligase activity
Contradicts
CHIP reduction in AD may be protective to limit toxic ubiquitinated fragment generation
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CHIP
No curated PDB or AlphaFold mapping for CHIP yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CHIP.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0053
Events (7d)
1
Price History
▲7.0%💾 Resource Usage
LLM Tokens
39,448
$0.1183
Total Cost
$0.1183
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary hippocampal neurons are treated with a blood-brain barrier-penetrant CHIP activator (compound dose 10mg/kg IP, twice daily for 7 days), THEN quantitative targeted proteomics (MRM) will dete | ≥40% reduction in GRIA1 and GRIA2 in synaptosomal fraction (p<0.01, Student's t-test), with no significant change in presynaptic marker synaptophysin, measured | — no observation — | pending | 0.55 |
| IF human iPSC-derived cortical neurons are transduced with CHIP/STUB1 overexpression lentivirus (≥3x endogenous levels), THEN quantitative immunoblot will show ≥50% reduction in PSD-95/DLG4 protein wi | ≥50% decrease in PSD-95 (DLG4) protein level with concurrent accumulation of high-molecular-weight ubiquitinated species, measurable by western blot with normal | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF human iPSC-derived cortical neurons are transduced with CHIP/STUB1 overexpression lentivirus (≥3x endogenous levels), THEN quantitative immunoblot will show ≥50% reduction in PSD-95/DLG4 protein within 48 hours post-transduction compared to GFP control, accompanied by increased polyubiquitinated
Predicted outcome: ≥50% decrease in PSD-95 (DLG4) protein level with concurrent accumulation of high-molecular-weight ubiquitinated species, measurable by western blot w
Falsification: PSD-95 levels remain unchanged (within 10% of control) or decrease is not blocked by proteasome inhibitor (MG-132 10μM, 6hr pretreatment), indicating degradation is not CHIP/proteasome-mediated
pendingconf 55%
IF primary hippocampal neurons are treated with a blood-brain barrier-penetrant CHIP activator (compound dose 10mg/kg IP, twice daily for 7 days), THEN quantitative targeted proteomics (MRM) will detect ≥40% reduction in AMPA receptor subunits GRIA1 and GRIA2 in synaptosomal fractions compared to ve
Predicted outcome: ≥40% reduction in GRIA1 and GRIA2 in synaptosomal fraction (p<0.01, Student's t-test), with no significant change in presynaptic marker synaptophysin,
Falsification: No significant change in GRIA1/GRIA2 levels (<20% change, p>0.05) or reduction is observed equally in non-synaptic compartments, or synaptophysin also decreases ≥40%, indicating non-specific toxicity
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.